Downregulation of integrins by von Hippel-Lindau (VHL) tumor suppressor protein is independent of VHL-directed hypoxia-inducible factor alpha degradation

Biochemistry and Cell Biology

Volumn 86, Issue 3, 2008, Pages 227-234

  Ji, Qingzhou ^a   Burk, Robert D ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Adherens junctions; HIF; Integrin; Tight junctions; VHL

Indexed keywords

DEGRADATION; MICROFLUIDICS; SULFATE MINERALS; TISSUE; TUMORS;

EXTRA-CELLULAR MATRIX (ECM); HYPOXIA-INDUCIBLE FACTOR (HIF); IN-CELL; INTEGRINS; RENAL CELL; TUMOR SUPPRESSOR GENES; TUMOR SUPPRESSORS;

GLYCOPROTEINS;

HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTEGRIN; PROTEASOME; PROTEIN SUBUNIT; TUMOR SUPPRESSOR PROTEIN; VON HIPPEL LINDAU PROTEIN;

ARTICLE; CARCINOGENESIS; CELL JUNCTION; CONTROLLED STUDY; DOWN REGULATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; KIDNEY CARCINOMA; OXYGEN CONCENTRATION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN TARGETING; TIGHT JUNCTION;

ADHERENS JUNCTIONS; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; DOWN-REGULATION; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOPRECIPITATION; INTEGRINS; KIDNEY; KIDNEY NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; TIGHT JUNCTIONS; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 44949139859     PISSN: 08298211     EISSN: None     Source Type: Journal    
DOI: 10.1139/O08-035     Document Type: Article

References (34)

1. Abdulrahman, M., Maina, E.N., Morris, M.R., Zatyka, M., Raval, R.R., Banks, R.E., et al. 2007. Identification of novel VHL targets that are associated with the development of renal cell carcinoma. Oncogene, 26: 1661-1672. doi:10.1038/sj.onc.1209932. PMID:17001320.
2. Anastassiou, G., Duensing, S., Steinhoff, G., Kirchner, H., Ganser, A., and Atzpodien, J. 1995. In vivo distribution of integrins in renal cell carcinoma: integrin-phenotype alteration in different degrees of tumor differentiation and VLA-2 involvement in tumor metastasis. Cancer Biother. 10: 287-292. PMID:8590894.
3. Bluyssen, H.A., Lolkema, M.P., van Beest, M., Boone, M., Snijckers, C.M., Los, M., et al. 2004. Fibronectin is a hypoxia-independent target of the tumor suppressor VHL. FEBS Lett. 556: 137-142. doi:10.1016/S0014-5793(03)01392- 9. PMID:14706840.
4. Calzada, M.J., Esteban, M.A., Feijoo-Cuaresma, M., Castellanos, M.C., Naranjo-Suarez, S., Temes, E., et al. 2006. von Hippel-Lindau tumor suppressor protein regulates the assembly of intercellular junctions in renal cancer cells through hypoxia-inducible factor-independent mechanisms. Cancer Res. 66: 1553-1560. doi:10.1158/0008-5472.CAN-05-3236. PMID:16452212.
5. Cavallaro, U., and Christofori, G. 2004. Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat. Rev. Cancer, 4: 118-132. PMID:14964308.
6. Davidowitz, E.J., Schoenfeld, A.R., and Burk, R.D. 2001. VHL induces renal cell differentiation and growth arrest through integration of cell-cell and cell-extracellular matrix signaling. Mol. Cell. Biol. 21: 865-874. doi:10.1128/MCB.21.3.865-874.2001. PMID:11154273.
7. Esteban, M.A., Harten, S.K., Tran, M.G., and Maxwell, P.H. 2006a. Formation of primary cilia in the renal epithelium is regulated by the von Hippel-Lindau tumor suppressor protein. J. Am. Soc. Nephrol. 17: 1801-1806. doi:10.1681/ASN.2006020181. PMID:16775032.
8. Esteban, M.A., Tran, M.G., Harten, S.K., Hill, P., Castellanos, M.C., Chandra, A., et al. 2006b. Regulation of E-cadherin expression by VHL and hypoxia-inducible factor. Cancer Res. 66: 3567-3575. doi:10.1158/0008-5472.CAN-05-2670. PMID:16585181.
9. Giancotti, F.G., and Ruoslahti, E. 1999. Integrin signaling. Science, 285: 1028-1032. doi:10.1126/science.285.5430.1028. PMID:10446041.
10. Grosfeld, A., Stolze, I.P., Cockman, M.E., Pugh, C.W., Edelmann, M., Kessler, B., et al. 2007. Interaction of hydroxylated collagen IV with the von hippel-lindau tumor suppressor. J. Biol. Chem. 282: 13264-13269. doi:10.1074/jbc.M611648200. PMID:17339318.
11. Guo, W., and Giancotti, F.G. 2004. Integrin signalling during tumor progression. Nat. Rev. Mol. Cell Biol. 5: 816-826. doi:10.1038/nrm1490. PMID:15459662.
12. Hergovich, A., Lisztwan, J., Barry, R., Ballschmieter, P., and Krek, W. 2003. Regulation of microtubule stability by the von Hippel-Lindau tumor suppressor protein pVHL. Nat. Cell Biol. 5: 64-70. doi:10.1038/ncb899. PMID:12510195.
13. Hoffman, M.A., Ohh, M., Yang, H., Klco, J.M., Ivan, M., and Kaelin, W.G., Jr. 2001. von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to down-regulate HIF. Hum. Mol. Genet. 10: 1019-1027. doi:10.1093/hmg/10.10.1019. PMID:11331612.
14. Hughes, M.D., Kapllani, E., Alexander, A.E., Burk, R.D., and Schoenfeld, A.R. 2007. HIF-2alpha downregulation in the absence of functional VHL is not sufficient for renal cell differentiation. Cancer Cell Int. 7: 13. doi:10.1186/1475-2867-7-13. PMID:17598890.
15. Hynes, R.O. 2002. Integrins: bidirectional, allosteric signaling machines. Cell, 110: 673-687. doi:10.1016/S0092-8674(02)00971-6. PMID:12297042.
16. Iliopoulos, O., Kibel, A., Gray, S., and Kaelin, W.G., Jr. 1995. Tumor suppression by the human von Hippel-Lindau gene product. Nat. Med. 1: 822-826. doi:10.1038/nm0895-822. PMID:7585187.
17. Kaelin, W.G., Jr. 2007. The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma. Clin. Cancer Res. 13: 680s-684s. doi:10.1158/1078-0432.CCR-06-1865. PMID:17255293.
18. Kawano, K., Kantak, S.S., Murai, M., Yao, C.C., and Kramer, R.H. 2001. Integrin alpha3beta1 engagement disrupts intercellular adhesion. Exp. Cell Res. 262: 180-196. doi:10.1006/excr.2000.5083. PMID:11139342.
19. Kessler, P.M., Vasavada, S.P., Rackley, R.R., Stackhouse, T., Duh, F.M., Latif, F., et al. 1995. Expression of the Von Hippel-Lindau tumor suppressor gene, VHL, in human fetal kidney and during mouse embryogenesis. Mol. Med. 1: 457-466. PMID:8521303.
20. Kim, W.Y., and Kaelin, W.G. 2004. Role of VHL gene mutation in human cancer. J. Clin. Oncol. 22: 4991-5004. doi:10.1200/JCO.2004.05.061. PMID:15611513.
21. Kondo, K., Kim, W.Y., Lechpammer, M., and Kaelin, W.G., Jr. 2003. Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth. PLoS Biol. 1: E83. doi:10.1371/journal.pbio.0000083. PMID:14691554.
22. Lenburg, M.E., Liou, L.S., Gerry, N.P., Frampton, G.M., Cohen, H.T., and Christman, M.F. 2003. Previously unidentified changes in renal cell carcinoma gene expression identified by parametric analysis of microarray data. BMC Cancer, 3: 31. doi:10.1186/1471-2407-3-31. PMID:14641932.
23. Lutz, M.S., and Burk, R.D. 2006. Primary cilium formation requires von hippel-lindau gene function in renal-derived cells. Cancer Res. 66: 6903-6907. doi:10.1158/0008-5472.CAN-06-0501. PMID:16849532.
24. Maxwell, P.H., Wiesener, M.S., Chang, G.W., Clifford, S.C., Vaux, E.C., Cockman, M.E., et al. 1999. The tumor suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature, 399: 271-275. doi:10.1038/20459. PMID:10353251.
25. Ohh, M., Yauch, R.L., Lonergan, K.M., Whaley, J.M., Stemmer-Rachamimov, A.O., Louis, D.N., et al. 1998. The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol. Cell, 1: 959-968. doi:10.1016/S1097-2765(00)80096-9. PMID:9651579.
26. Paraf, F., Chauveau, D., Chretien, Y., Richard, S., Grunfeld, J.P., and Droz, D. 2000. Renal lesions in von Hippel-Lindau disease: immunohistochemical expression of nephron differentiation molecules, adhesion molecules and apoptosis proteins. Histopathology, 36: 457-465. doi:10.1046/j.1365-2559. 2000.00857.x. PMID:10792488.
27. Roe, J.S., Kim, H., Lee, S.M., Kim, S.T., Cho, E.J., and Youn, H.D. 2006. p53 stabilization and transactivation by a von Hippel-Lindau protein. Mol. Cell, 22: 395-405. doi:10.1016/j.molcel.2006.04.006. PMID:16678111.
28. Schoenfeld, A.R., Davidowitz, E.J., and Burk, R.D. 1998. A second major native von Hippel-Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor. Proc. Natl. Acad. Sci. U.S.A. 95: 8817-8822. doi:10.1073/pnas.95.15.8817. PMID:9671762.
29. Schoenfeld, A.R., Davidowitz, E.J., and Burk, R.D. 2000. Elongin BC complex prevents degradation of von Hippel-Lindau tumor suppressor gene products. Proc. Natl. Acad. Sci. U.S.A. 97: 8507-8512. doi:10.1073/pnas.97.15.8507. PMID:10900011.
30. Stickle, N.H., Chung, J., Klco, J.M., Hill, R.P., Kaelin, W.G., Jr., and Ohh, M. 2004. pVHL modification by NEDD8 is required for fibronectin matrix assembly and suppression of tumor development. Mol. Cell. Biol. 24: 3251-3261. doi:10.1128/MCB.24.8.3251-3261.2004. PMID:15060148.
31. Wang, Y., Jin, G., Miao, H., Li, J.Y., Usami, S., and Chien, S. 2006. Integrins regulate VE-cadherin and catenins: dependence of this regulation on Src, but not on Ras. Proc. Natl. Acad. Sci. U.S.A. 103: 1774-1779. doi:10.1073/pnas.0510774103. PMID:16446427.
32. Wykoff, C.C., Pugh, C.W., Maxwell, P.H., Harris, A.L., and Ratcliffe, P.J. 2000. Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumor suppressor by mRNA differential expression profiling. Oncogene, 19: 6297-6305. doi:10.1038/sj.onc. 1204012. PMID:11175344.
33. Yamada, A., Fujita, N., Sato, T., Okamoto, R., Ooshio, T., Hirota, T., et al. 2006. Requirement of nectin, but not cadherin, for formation of claudin-based tight junctions in annexin II-knockdown MDCK cells. Oncogene, 25: 5085-5102. doi:10.1038/sj.onc.1209167. PMID:16607281.
34. Yu, F., White, S.B., Zhao, Q., and Lee, F.S. 2001. HIF-1alpha binding to VHL is regulated by stimulus-sensitive proline hydroxylation. Proc. Natl. Acad. Sci. U.S.A. 98: 9630-9635. doi:10.1073/pnas.181341498. PMID:11504942.